Overture to continue
Wednesday, 11 June, 2008
Independent regulators have recommended the continuation of the Ovature ovarian cancer trial, being run by Novogen's (ASX: NRT) subsidiary Marshall Edwards.
The trial's Independent Data Monitoring Committee (IDMC) recommended the continuation of the phase III trial of the orally administered investigational drug phenoxodiol, a chemosensitising agent, in women with advanced, refractory ovarian cancer.
The trial is being run to determine its safety and effectiveness when used in combination with carboplatin.
The trial has been approved by the US FDA under a special protocol assessment program. It is recruiting patients in clinical sites across the US, UK, Europe and Australia.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
